Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4280)	5/10/1998 9:44:00 AM
From: PAL	Respond to of 6136

From SDU-T May 10, 1998: Viracept, the anti-AIDS product by Agouron Pharmaceuticals, "has captured 30 percent of the HIV protease inhibitor market and continues to gain on the current market leader, Merck's Crixivan," says Elise T. Wang of Paine Webber. The Agouron dcrug is safer and has fewer side effects, the analyst says. Wang looks for the company to earn $ 1.56 a share this year and $ 1.92 next year, up from a loss of $ 1.07 in 1997. The stock is lsted as one of Paine Webber's "Analysts' Best Calls." Now just suppose Elise is a reporter for New York Times ...